SCHEDULE: 1Globe Capital Discloses 6.45% Stake in Crescent Biopharma

1Globe Capital LLC and its Chairman, Jiaqiang Li, have disclosed a passive beneficial ownership of 6.45% in Crescent Biopharma, Inc., totaling 896,712 ordinary shares.

Summary

• 1Globe Capital LLC and Jiaqiang Li reported beneficial ownership of 896,712 ordinary shares of Crescent Biopharma, Inc.
• This represents 6.45% of the company's outstanding ordinary shares.
• The ownership is passive, meaning the shares were not acquired or held for the purpose of changing or influencing control of the issuer.
• The percentage is based on 13,892,562 shares outstanding as of July 25, 2025, as disclosed in the Issuer's Form 10-Q filed on May 14, 2025.
• Jiaqiang Li, as Chairman of 1Globe Capital LLC, directly or indirectly exercises voting and dispositive power over these shares.

Sentiment

Score: 7

Explanation: The disclosure of a new significant passive stake by an institutional investor and its chairman can be viewed positively as it signals confidence in Crescent Biopharma, Inc.

Positives

• A significant institutional investor, 1Globe Capital LLC, and its Chairman, Jiaqiang Li, have taken a substantial stake in Crescent Biopharma, Inc., indicating confidence in the company's prospects.
• The filing explicitly states the ownership is passive, which may alleviate concerns about potential hostile takeover attempts or disruptive activist campaigns.

Negatives

• The filing itself does not present any negative financial or operational information about Crescent Biopharma, Inc. It is purely a disclosure of ownership.

Risks

• While the filing states the ownership is passive, a large concentration of shares by a single entity could still influence future corporate decisions or share price volatility if their investment strategy changes.
• The beneficial owner, Jiaqiang Li, is a citizen of China, which could introduce geopolitical considerations or regulatory scrutiny depending on the nature of Crescent Biopharma's business.

Future Outlook

NA

Management Comments

• Jiaqiang Li serves as the Chairman of 1Globe Capital LLC and directly or indirectly exercises voting and dispositive power over the Issuer's shares held by 1Globe Capital LLC and as such, Mr. Li may be deemed the ultimate beneficial owner of such shares.
• Each Reporting Person disclaims beneficial ownership of such securities that are not directly owned by such Reporting Person, except to the extent of its or his pecuniary interest therein.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing indicates a significant investment in a biopharma company by a capital management firm. In the biopharma sector, such investments can signal confidence in a company's pipeline, technology, or market position, especially from a firm like 1Globe Capital LLC.

Stakeholder Impact

• Shareholders: The entry of a new significant shareholder may be perceived as a positive signal, potentially increasing investor confidence and demand for the stock.
• Management: While the ownership is passive, management may view this as a vote of confidence in their strategy and operations.

Key Dates

Recommendation

The filing indicates a new significant passive ownership stake, which is generally a positive signal of investor confidence. However, without additional financial or operational data from Crescent Biopharma, Inc., a definitive "buy" or "sell" recommendation cannot be made solely based on this ownership disclosure. A "hold" recommendation is appropriate as it suggests monitoring the company's performance and future disclosures in light of this new significant shareholder.

Keywords

Crescent Biopharma, 1Globe Capital, Jiaqiang Li, Schedule 13G, beneficial ownership, passive investment, ordinary shares, biopharma, institutional investor